CRISPR Therapeutics AG 2024年度报告

FORM 10-K (Mark One)☐ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934For the fiscal year ended December 31, 2024OR☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 FOR THE TRANSITION PERIOD FROMTOCommission File Number 001-37923 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(b) of the Act: Securities registered pursuant to Section 12(g) of the Act:None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES☐NO☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES☐NO☐ Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required tofile such reports), and (2) has been subject to such filing requirements for the past 90 days. YES☐NO☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for suchshorter period that the registrant was required to submit such files). YES☐NO☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☐Smaller reporting company☐ Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the ExchangeAct.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of theeffectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered public accounting firm that prepared or issued its audit report.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of theregistrant included in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to§240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES☐NO The aggregate market value of the common shares held by non-affiliates of the Registrant was approximately $4.3 billion,based on the closing price on the Nasdaq Global Market of the Registrant’s common shares on June 28, 2024 (the last tradingday of the Registrant’s second fiscal quarter of 2024). The number of the Registrant’s common shares outstanding as of February 7, 2025 was 85,774,474. DOCUMENTS INCORPORATED BY REFERENCE Portions of the Registrant’s Definitive Proxy Statement relating to the 2025 Annual General Meeting of Shareholders, whichthe Registrant intends to file with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days afterthe end of the Registrant’s fiscal year ended December 31, 2024, are incorporated by reference into Part III of this Report. Table of Contents Page PART I Item1.BusinessItem1A.Risk FactorsItem1B.Unresolved Staff CommentsItem1C.CybersecurityItem2.PropertiesItemLegal Proceedings 3.Item4. Mine Safety Disclosures PARTII Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchasesof Equity Securities93Reserved96Management’s Discussion and Analysis of Financial Condition and Results of Operations96Quantitative and Qualitative Disclosures About Market Risk107Financial Statements and Supplementary Data107Changes in and Disagreements with Accountants on Accounting and Financial Disclosure107Controls and Procedures107Other Information110Disclosure Regarding Foreign Jurisdictions that Prevent Inspections110 PART Executive Compensation Security Ownership of Certain Beneficial Owners and Management and Related StockholderMatters111Certain Relationships and Related Transactions, and Director Independence111 Principal Accountant Fees and Services PARTIVItem15.Item16. Exhibits and Financial Statement Schedules Risk Factor Summary Our business is subject to a number